Affimed (NASDAQ:AFMD) released its quarterly earnings results on Tuesday. The biopharmaceutical company reported ($0.11) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.13) by $0.02, MarketWatch Earnings reports. Affimed had a negative net margin of 280.35% and a negative return on equity of 135.08%. The company had revenue of $5.66 million for the quarter, compared to analyst estimates of $8.51 million.
Shares of AFMD stock opened at $4.63 on Friday. Affimed has a 1 year low of $1.42 and a 1 year high of $4.66. The firm’s fifty day simple moving average is $3.06 and its 200 day simple moving average is $2.54. The firm has a market capitalization of $311.82 million, a P/E ratio of -6.81 and a beta of 2.78. The company has a current ratio of 3.01, a quick ratio of 3.00 and a debt-to-equity ratio of 0.01.
A number of brokerages recently issued reports on AFMD. Zacks Investment Research lowered shares of Affimed from a “buy” rating to a “hold” rating in a research report on Tuesday. SVB Leerink boosted their target price on shares of Affimed from $7.00 to $8.00 and gave the stock an “outperform” rating in a research report on Wednesday. Finally, BidaskClub raised shares of Affimed from a “hold” rating to a “buy” rating in a research report on Wednesday. One analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. Affimed currently has an average rating of “Buy” and a consensus price target of $7.33.
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. Its lead product candidate is AFM13, a natural killer cell (NK-cell) TandAb, which is in Phase 2a clinical study of relapsed CD30-positive lymphoma and Phase 1b clinical study of anti-PD-1 antibody Keytruda (pembrolizumab) in patients with relapsed Hodgkin lymphoma.
Read More: How to Invest in Marijuana Stocks
Receive News & Ratings for Affimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affimed and related companies with MarketBeat.com's FREE daily email newsletter.